医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Lianhua Qingwen Selected as Recommended Medicine in China’s Diagnosis and Treatment Protocol for COVID-19

2020年12月05日 PM12:00
このエントリーをはてなブックマークに追加


 

SHIJIAZHUANG CITY, China

Recently, China’s National Health Commission and State Administration of Traditional Chinese Medicine jointly-published The Diagnosis and Treatment Protocol for COVID-19 (Trial Version 8), recommending that Lianhua Qingwen Capsule, a Chinese traditional medicine, be used during the medical observation period of COVID-19 patients.

Lianhua Qingwen’s selection to the protocol demonstrates the recognition from Chinese authorities of its outstanding performance to control COVID-19 in China. It is learned that during the pandemic, Lianhua Qingwen has been widely used in designated hospitals and medical institutions in China, and has become the most recommended Chinese medicine in the COVID-19 treatment programs from the country’s provinces and municipalities.

This is not the first time that Lianhua Qingwen came into public view as an official recommended medicine in China. In 2003, Lianhua Qingwen was developed by Yiling Pharmaceutical in response to the “SARS” pandemic. Research of its effect on SARS from the Academy of Military Medical Sciences in China has revealed that it could significantly inhibit the replication of SARS virus. In 2015 when another coronavirus caused the Middle East respiratory syndrome, the National Health Commission also explicitly recommended Lianhua Qingwen Capsule as the preventive medical treatment medicine in its plan.

Lianhua Qingwen Capsule has recently been approved by the Food and Drug Administration of the Philippines and entered the Philippine market on November 23. In view of its crucial role played in major public health events, the Philippine experts hope that Lianhua Qingwen will be helpful to effectively combat COVID-19 in Philippines after entering the market and provide assistance for the Philippine government and people.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201204005157/en/

CONTACT

First Name: Li

Last Name: Kristy

E-mail:kristyli@chuhaimedia.com.cn

Phone No.: +86 85962566

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • サラダックス・バイオメディカル、サルバトーレ・J・サラモネ博士が権威ある C.E. Pippenger博士賞を受賞したと発表
  • Japan’s MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer
  • VFMCRP announces approval for TAVNEOS® (avacopan) for the treatment of ANCA-associated vasculitis in Japan
  • TAE Life Sciences Announces Installation of First Accelerator-based Neutron Beam System for Biologically Targeted Radiation Therapy at Xiamen Humanity Hospital in China
  • New Study Evaluates the Feasibility of Using Masimo EMMA® Capnography on Mechanically Ventilated Neonates